Skye Bioscience soars after experimental weight-loss drug shows promise in mice

ReutersApr 15, 2025 2:32 PM

Shares of drug developer Skye Bioscience SKYE.O rise as much as 185% to a near three-month high of $3.73; last up 65.3% in morning trade

Stock is set for its best day in over a year, if gains hold

Co says its drug candidate, nimacimab, showed 23.5% weight loss in mice, comparable to Eli Lilly's LLY.N popular drug, tirzepatide, sold as Zepbound, and Novo Nordisk's NOVOb.CO experimental drug, monlunabant

SKYE also says nimacimab, when combined with tirzepatide, showed a greater than 30% weight loss

Initial data from SKYE's mid-stage study in obesity is expected in late Q3/early Q4 2025

Including session's move, stock down 23% YTD

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

Storage Chip Giant SanDisk Replaces TEAM to Join Nasdaq 100 Index, SanDisk Shares May Soar to $1,000

TradingKey — Last Friday, Nasdaq announced that memory chip giant SanDisk (SNDK) will join the Nasdaq 100 Index before the market opens on April 20, 2026, replacing Atlassian (TEAM).

Trump Blockade of Strait of Hormuz Drives Oil Price Surge, Will This Be Another TACO?

TradingKey - On Sunday (April 13), Donald Trump announced that following the breakdown of U.S.-Iran negotiations, the U.S. Navy will implement a naval blockade on Iranian ports starting Monday.

Up 20% in Five Days, Over 50% This Year: Why Was Marvell Technology Tapped by Nvidia?

TradingKey - Since April 2026, Marvell Technology (MRVL) has demonstrated sustained stock price strength. On April 10, the shares closed at $128.49, up 7.14% for the day. The stock has seen a cumulative gain of nearly 20% over the past five trading days, with an overall increase of 29.72% in April.

Musk’s XChat Is Coming to App Store, Meta, Apple and Finance World Are Trembling

Elon Musk’s XChat, the Western equivalent of WeChat, is set to launch on the App Store, issuing a direct challenge to giants such as Meta, Apple, and PayPal.

Microsoft Launches Its Own AI Models and Ditches OpenAI Dependence - Is MSFT Stock a Buy at $370?

Microsoft at $370 is a 17%-revenue-growth, 47%-margin, $625-billion-backlog business trading at a multi-year low valuation, because the market is scared of macro noise. The AI model releases this week prove the moat is deepening, not narrowing.

Featured Tools